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WE investigated the influence of recombinant human tu-
mour necrosis factor alpha (TNF-tx) and its derivatives
termed muteins liI, V, VI--in which the first 3 to 7 amino
acids ofnativeTNF- have been replaced---on the survival
time of mice inoculated with leukaemia L1210 or leukae-
mia P338. TNF-tx prolonged the survival of mice with
leukaemia L1210 but did not have any therapeutic activity
in leukaemia P388-bearing mice. Muteins-treated mice
with leukaemia P388 Hved longer than animals receiving
TNF-x, while those inoculated with leukaemia L1210 did
not show any significant prolongation of life compared
with the TNF-tx treated group. The results presented
in this report indicate that the antileukaemic activity of
TNF-tz is governed at least in part by the nature of the
N-terminal amino acids.
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Introduction
The multifunctional cytokine tumour necrosis fac-
tor-{x (TNF-(x) plays a role in the regulation of many
biological responses in vivo, and has been implicated
in a wide range of pathological conditions, including
the host response to leukaemia growth. 1-5 As for
cytokines in general, the first event in triggering a
cellular response is a specific high affinity interaction
with membrane receptor molecules initiating a cas-
cade of signal transfer reactions inside the cell. How-
ever, although two cell surface receptors for TNF-et
have been identified, the amino acid residues neces-
sary for the biological activity of TNF-0t have not
been characterized. Experiments performed with
derivatives of TNF-( termed muteins, in which the
first 3 to 7 amino acids of native TNF-(x have been
replaced, indicate that the receptor-binding domain
of TNF-(x may be located near the N-terminus of the
molecule.6,7 In the present study we compare the
antitumour effects of TNF-(x and its N-terminal region
muteins in murine leukaemia model.
Materials and Methods
Animals: All the mice used in this experiment were
produced at the Institute of Immunology and Experi-
mental Therapy, Polish Academy of Sciences,
WrocIaw. At the time of initiation of the experiment
they were young adults, 8-12 weeks old. They were
given standard laboratory food and water ad libitum.
In this study, female mice of DBA/2 strain were used.
Leukaemias: Leukaemia L1210 and P388 were ob-
tained from the Institute of Immunology and Experi-
mental Therapy, Polish Academy of Sciences,
Wrocl’aw, and were maintained by serial passage in
the ascitic fluid of DBA/2 mice. Leukaemic cells from
the fluid were resuspended in 0.9% sodium chloride
such that 106 leukaemia L1210 or P388 cells were
injected i.p. into DBA/2 recipients.
Cytokines: TNF-( and its muteins’ syntheses and
biochemical analyses were performed in the Depart-
ment of Bioorganic Chemistry, L6d., Poland. Pro-
duction of TNF muteins were supported by the
Committee for Scientific Research Grant No.
662889203 to M.K. and B.S. Recombinant human
TNF-(, had a specific activity of 2 x 107 U/mg. Muteins
III, V, VI were constructed using synthetic
oligonucleotides to introduce changes in the DNA
sequence, encoding the 7 N-terminal amino acids of
native TNF-(. The DNA was expressed in
Escherichia coli, and the resulting muteins were
purified by ion exchange chromatography. Amino
acid sequences were analysed by automated Edman
degradation using an Applied Biosystems ABI 477A
protein sequencer. The N-terminal amino acids se-
quences of TNF-0t and its muteins are shown in Table
1. Endotoxin contamination amounted to approxi-
mately 1.9 ng endotoxin per mg protein, as estimated
using a commercially available assay (Sigma Chemi-
cal Co., St Louis, MI, USA). Recombinant cytokines
were reconstituted using sterile phosphate-buffered
saline (PBS), and premixed at a concentration such
that all doses were injected in 0.2 ml.
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Table 1. The N-terminal amino acids sequences of TNF-(x and its
muteins
TNF-x
Mutein III
Mutein V
Mutein Vl
VaI-Arg-Ser-Ser-Ser-Arg-Thr-
Arg-His-Arg-His-
VaI-Arg-Ser-Ser-Ile-Val-Ile-
Met-Arg-Ile-Arg-Met-
Met-methionine; Val-valine; Arg-arginine; Ser-serine;
Thr-threonine; Lys-lysine; His-histidine; Ile-isoleucine.
Treatment: Animals received tumour challenges on
day 0, and all treatments were initiated i.p. on the
following day. Cytokines were administered at doses
of 250 and 400 t.tg/kg as daily injections for 8 days or
at a dose of 400 l.tg/kg given 2, 4, 6 and 8 days after
the inoculation of leukaemic cells. The control group
of mice received i.p. injections of PBS.
Antileukaemic assay: Animals were observed daily
for survival for a minimum of 60 days. The median
survival time (MST) was assessed as follows: MST
(x + y)/2, where ’x’ denotes the earliest day when
the number of dead animals > n/2, ’y’ denotes
the earliest day when the number of dead animals
> (n/2)+ 1, and ’n’ denotes the number of animals
in that group. Therapy efficacy against leukaemia
was assessed as a percentage of median survival time
of the treated group (T) to that of the control group
(C): T/C MSTT/MSTc x 100.
Statistical analysis: Statistical analysis was performed
using Student’s t-test. Results were considered sig-
nificant when the p value was < 0.05.
Results
Different treatment regimes with TNF-0t or its
muteins III, V, VI against the two types of murine
leukaemias were studied to compare their
antitumour activities. As shown in Table 2, TNF-0t
prolonged survival of leukaemia L1210-bearing mice
when given daily at a dose of 2501.tg/kg
(0.01 >p > 0.001), but shortened it when given at a
dose of 400 I.tg/kg (p < 0.001). Sequential application
ofTNF- at a dose of 400 t.tg/kg did not significantly
change the lifetime of mice with leukaemia L1210,
but was better tolerated than the same dose applied
in a daily treatment regime (0.01 >p > 0.001)
(Table 3). Conversely, TNF- muteins did not show
any therapeutic activity against leukaemia L1210
when used daily at a dose of 250 I.tg/kg, but had
a comparable therapeutic effect, except mutein
III to native TNF-0t, when used at a dose of
400 l.tg/kg, either in daily or sequential injections
(0.01 >p > 0.001) (Tables 2 and 3). There were no
significant changes in lifetime, either for daily or for
sequential application, between the groups of mice
receiving different TNF-{x muteins (Tables 2 and 3).
Table 2. The influence of TNF-(x and its muteins, administered
daily, on the survival time of mice with leukaemia L1210
Therapeutics MST X +/- SD T/C
(days)
Cytokine Dose
(lg/kg)
None PBS 7.0 6.8 +/- 0.5
TNF-(x 250 10.5" 10.5 +/- 0.9* 150"
400 5.0* 5.2 +/- 0.5* 71"
Mutein III 250 7.0 7.2 +/- 0.8 100
400 8.5 8.7 + 1.1 121
Mutein V 250 7.0 7.0 +/- 0.6 100
400 9.0* 9.2 +/- 1.2* 129"
Mutein VI 250 7.5 7.4 +/- 0.9 107
400 9.0* 9.1 +/- 0.9* 129"
Treatment, once a day, in eight i.p. injections or less if the survival
was shorter.
PBS, phosphate buffered saline given once a day, in eight i.p.
injections or less if the survival was shorter.
MST, median survival time. Six mice were used per group.
Mean values and standard deviations.
T/C,
MST of the treated group x 100 (%)
MST of the control group
Statistical significance compared with the control group.
Table 3. The influence of TNF-(x and its muteins, administered
every 48 h, on the survival time of mice with leukaemia L1210
Therapeutics" MST X +/- SD T/C
(days)
Cytokine Dose
(g/kg)
None PBS 7.0 6.8 +/- 0.5
TNF-x 400 7.5 8.0 +/- 1.0 107
Mutein III 400 8.5 8.8 +/- 1.0 121
Mutein V 400 9.0* 9.1 +/- 1.3* 129"
Mutein Vl 400 9.5* 9.6 +/- 1.1" 136"
Treatment, four i.p. injections on days 2, 4, 6, 8 of experiment.
PBS, phosphate buffered saline given in four i.p. injections on
days 2, 4, 6, 8 of experiment.
MST, median survival time. Six mice were used per group.
Mean values and standard deviations.
"T/C,
MST of the treated group x 100 (%)
MST of the control group
Statistical significance compared with the control group.
The survival time of leukaemia P388-bearing mice
receiving TNF- or its mutein V, either 250 btg/kg in
daily or 400 l.tg/kg in sequential injections, was
almost the same as that of the control group (Tables
4 and 5). Daily injections of 400 btg/kg of these
cytokines shortened the lifetime of mice compared
with animals from the control group (p < 0.001). The
lifetime of mice treated with mutein III or VI, at daily
doses of 250 or 400 I.tg/kg, did not differ significantly
from that observed in the control group (Table 4).
Sequential application of 400 btg/kg of these muteins
significantly prolonged the survival time of leukae-
mia P388-bearing mice in comparison with TNF-0t,
mutein V or control mice (0.01 >p>0.001). The
longest survival time was seen in the group receiving
mutein VI in the sequential treatment schedule
(Table 5).
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Table 4. The influence of TNF-(z and its muteins, administered
daily, on the survival time of mice with leukaemia P388
Therapeutics MST X + SD T/C
(days)
Cytokine Dose
(lg/kg)
None PBS 10.0 10.5 + 0.5
TNF-c 250 11.0 11.0 + 0.6 110
400 8.0 8.0 + 0.9 80
Mutein III 250 11.0 11.2 + 0.6 110
400 11.5 11.5 + 0.5 115
Mutein V 250 11.0 10.9 + 0.8 110
400 8.0 8.0 + 0.5 80
Mutein VI 250 11.5 11.6 + 0.9 115
400 10.0 9.8 +/- 0.8 100
Treatment, once a day, in eight i.p. injections or less if the survival
was shorter.
PBS, phosphate buffered saline given once a day, in eight i.p.
injections or less if the survival was shorter.
MST, median survival time. Six mice were used per group.
Mean values and standard deviations.
T/C, MST of the treated group x 100 (%)
MST of the control group
*Statistical significance compared with the control group.
Table 5. The influence of TNF- and its muteins, administered
every 48 h, on the survival time of mice with leukaemia P388
Therapeutics" MST X +/- SD T/C
(days)
Cytokine Dose
(lg/kg)
None PBS 10.0 10.5 +/- 0.5
TNF-o 400 11.0 11.2 +/- 0.6 110
Mutein III 400 13.0* 13.2 + 0.5* 130"
Mutein V 400 9.5 9.5 +/- 0.6 95
Mutein VI 400 14.0" 14.2 +/- 1.1 140"
"Treatment, four i.p. injections on days 2, 4, 6, 8 of experiment.
PBS, phosphate buffered saline given in four i.p. injections on
days 2, 4, 6, 8 of experiment.
MST, median survival time. Six mice were used per group.
Mean values and standard deviations.
T/C, MST of the treated group x 100 (%)
MST of the control group
*Statistical significance compared with the control group.
Discussion
TNF- is a cytokine which holds strong promise
for application in cancer therapy because of its
marked antiproliferative effects against various tu-
mour cell lines in both in vitro and in vivo condi-
tions.9-15 Originally defined as an antitumoural agent,
it is now recognized as a mediator of inflammation
and cellular immune responses. The first step in the
induction of these activities is the binding of TNF-
to specific cell surface receptors. Two such receptors,
termed p55 and p75, have recently been cloned, 16,17
although the TNF- domain responsible for
receptors binding has not been precisely identified.
Experiments performed with antibodies generated
against amino acids 1-31 of TNF-ot support the con-
cept that the receptor-binding domain of TNF-{x may
be located near the N-terminus of the TNF-ot
molecule. 7,18,19 In this work we have compared the
antitumour effects of TNF-ot and its derivatives
termed muteins III, V, VI, in which the first 3 to 7
amino acids of native TNF-ot have been replaced,
against two kinds of murine leukaemias, using two
different therapy regimens.
The results of our previous4,5 and present studies
show that submaximally and maximally tolerated
doses of TNF-ot are those of maximum antitumour
effectiveness. Daily administration of this cytokine is
more effective than sequential application, although
sequential administration of TNF-ot seems to be less
toxic than this observed in daily protocol. Yet, nei-
ther the dose nor the schedule mentioned above had
any therapeutic activity in leukaemia P388-bearing
mice. Thus, not only dosage, but also duration and
sequence of TNF administration, as well as the type
of target neoplasia, seem to be of key value in the
treatment strategy. An important thing in understand-
ing the mechanisms of antitumour activity of this
cytokine is to explain how selectivity is achieved
with respect to the diverse TNF-o responses in differ-
ent cell types and tissues. A clue to understanding
this mechanism may come from tudies defining the
amino acid requirements for the biological activity of
TNF_0.6.7.20-22
From the data of others it is known that an increase
in basicity of the N-terminal segment of TNF-0t im-
proves its cytotoxic activity.
7,z This observation is
consistent with our finding that the basic mutein III
has more expressed antileukaemic activity than the
native molecule of TNF-c. It should be stressed that
this mutein binds to both TNF-0t receptors, as indi-
cated in in vitro studies on human epithelioid carci-
noma cells (HeLa cells) or Burkitt lymphoma cells
(Jijoye cells). This is in contrast with observations
concerning mutein VI, which does not bind to any of
TNF-0t receptors, either on HeLa or Jijoye cells, and
exhibits extremely cytotoxic effect in vitro, as well
as in our P388 murine leukaemia model. Interest-
ingly, this mutein exhibits very subtle
proinflammatory effect and fails to induce
endothelial cell responses, including expression of
intercellular adhesion molecule-1 (ICAM-1) and se-
cretion of interleukin 6 (IL-6). 6,7 In addition, experi-
mental mice exhibit much better tolerance of high
doses of mutein VI compared with native TNF-,
since daily injections of 400 lag/kg of mutein VI
significantly prolonged the survival time of mice
compared with TNF- treated group, whose lifetime
was even shorter than that observed in control ani-
mals. These results suggest that the modification of
N-terminal region of TNF- augments and/or alters
mechanisms of antitumour action of the native mol-
ecule of TNF-0t and allows the minimizing of the side
effects of therapy with this cytokine. Mutein V, which
in vitro appears to exert its effect through an inter-
action with p75 TNF- receptor, caused only slight
Mediators of Inflammation. Vol 3. 1994 41:3K. Warzocha et al.
prolongation of life of leukaemia L1210-bearing
mice, and no effect against leukaemia P388. This is
in agreement with in vitro observations, indicating
that cytotoxic as well as proinflammatory effects of
mutein V represent intermediate level compared with
native molecule of TNF-ot on the one hand, and
mutein III or VI on the other.6,7
In the past few years, a number of experimental
observations were made that have provided insights
into the cytotoxic mechanism of TNF-z action. The
question of structure-function relationship to TNF<z
activity seems to be an important clue in the under-
standing of the operation of the TNF4z-signalling
system. The results presented in this report and the
observations of others indicate that mechanisms of
TNF4z cytotoxic ,action are governed at least in part
by the nature of the N-terminal amino acids. Further
studies will hopefully yield a cohesive model of how
TNF4z shares its biological activities, and will allow
more rational transposing of the positive preclinical
data into effective clinical treatment regimens.
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